Comparison between CA19-9,CEA and specific N-Glycans in early middle stage pancreatic carcinoma serum
10.11904/j.issn.1002-3070.2015.01.002
- VernacularTitle:早中期胰腺癌患者血清特异性糖链与CA19-9、CEA 检测比较的研究
- Author:
Chao ZHAN
;
Yu JIN
;
Yubao ZHANG
- Publication Type:Journal Article
- Keywords:
Pancreatic carcinoma;
N-Glycans;
CA19-9;
CEA
- From:
Practical Oncology Journal
2015;(1):7-11
- CountryChina
- Language:Chinese
-
Abstract:
Objective To test and compare CA19-9,CEA with Specific N-Glycans in early-middle stage pancreatic carcinoma serum to find a better tumor marker in early pancreatic carcinoma .Methods To find the difference of N-Glycans structure ,DSA-FACE was performed in 35 early middle stage pancreatic carcinoma patients and 50 healthy human .Meanwhile ,we tested CA19-9 and CEA in the pancreatic carcinoma patients at the same stage.Result The serum N -glycan profiles of pancreatic carcinoma was identified by the DSA -FACE technique.The results showed that between pancreatic carcinoma patients and healthy persons ,there were significant differences in N -glycans.The peak 13,14 and 17 were the most significant peaks which would be most likely picked as a new tumor marker of pancreatic carcinoma .Taking log(p14 ×p17/p13)as indicator of the ROC curve analysis,and the area under ROC curve was 0.799 ±0.050 with 84.9% sensitivity and 68% speci-ficity.Meanwhile,the sensitivity of CA19-9 was 61.2%,the sensitivity of CEA was 11.7%.Conclusion The Peak 13,14 and 17 are the most significant peaks which would be picked as a new tumor marker of pancreatic carcinoma.Espicially,its sensitivity is superior to CA19-9、CEA for early middle stage patients .
